1
John S Kent, Danny H Lewis, Lynda M Sanders, Thomas R Tice: Microencapsulation of water soluble active polypeptides. Syntex, Ellen J Wise, Tom M Moran, Alan Krubiner, June 23, 1987: US04675189 (333 worldwide citation)

This invention concerns novel sustained release microcapsule compositions comprising water-soluble, hormonally active polypeptides and, optionally, a polymer hydrolysis modifying agent encapsulated in a biocompatible, biodegradable polymer.


2
Lynda M Sanders, Abraham Domb: Delayed/sustained release of macromolecules. Syntex, David A Lowin, John A Dhuey, September 25, 1990: US04959217 (261 worldwide citation)

This invention concerns novel, delayed/sustained release devices and compositions, including methods of their manufacture and use. The compositions include macromolecules, particularly polypeptide pharmaceuticals, and an initially partially-hydrated, non-biodegradable, hydrogel rate-limiting membran ...


3
Lynda M Sanders, Ramon A Burns Jr: Delivery systems for the controlled administration of LHRH analogs. Syntex, Tom M Moran, Lester E Johnson, July 2, 1991: US05028430 (20 worldwide citation)

An implantable polymeric delivery system for the controlled and continuous administration of an LHRH agonist which comprises a silicone elastomer matrix in which is dispersed about 30 to about 42 weight percent of water-soluble particulate phase containing an LHRH analog or a pharmaceutically accept ...


4
Brian H Vickery, Eric J Benjamin, Cherng Chyi Fu, Lynda M Sanders: Intranasal administration of polypeptides in powdered form. Pfizer Corporation, Heller Ehrman White & McAuliffe, November 9, 2004: US06815424 (18 worldwide citation)

Pharmaceutical compositions of biologically active polypeptides in powder form suitable for nasal administration, comprising a therapeutically effective amount of a biologically active polypeptide and a water-soluble polysaccharide.


5
Brian H Vickery, Eric J Benjamin, Cherng Chyi Fu, Lynda M Sanders: Intranasal administration of LHRH polypeptides in powdered form. Pharmacia Corporation, Heller Ehrman White & McAuliffe, February 18, 2003: US06521597 (3 worldwide citation)

Pharmaceutical compositions of biologically active polypeptides in powder form suitable for nasal administration, comprising a therapeutically effective amount of a biologically active polypeptide and a water-soluble polysaccharide.


6
Giovanni M Pauletti, Kishorkumar J Desai, Susan L Roweton, Donald C Harrison, Lynda M Sanders: Therapeutic compositions for drug delivery to and through covering epithelia. Hana Verny, Peters Verny Jones & Schmitt, August 5, 2004: US20040151774-A1

Polymer foams and films for delivery of therapeutic agents to and through nasal, oral or vaginal mucosa and cornified or non-cornified epithelium of labia and scrotum. Polymer foams or absorbable or non-absorbable films containing a therapeutic agent incorporated therein wherein said agent is releas ...


7
Brian H Vickery, Eric J Benjamin, Cherng Chyi Fu, Lynda M Sanders: Intranasal administration of polypeptides in powdered form. Heller Ehrman White & Mcauliffe, September 25, 2003: US20030181387-A1

Pharmaceutical compositions of biologically active polypeptides in powder form suitable for nasal administration, comprising a therapeutically effective amount of a biologically active polypeptide and a water-soluble polysaccharide.


8
Brian H Vickery, Eric J Benjamin, Cherng Chyi Fu, Lynda M Sanders: Intranasal administration of polypeptides in powdered form. Heller Ehrman White & Mcauliffe, April 28, 2005: US20050089480-A1

Pharmaceutical compositions or biologically active polypeptides in powder form suitable for nasal administration, comprising a therapeutically effective amount of a biologically active polypeptide and a water-soluble polysaccharide.